Pieris Pharmaceuticals (PIRS) Given Daily News Sentiment Rating of 0.02

News coverage about Pieris Pharmaceuticals (NASDAQ:PIRS) has trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.4956079986013 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

PIRS has been the topic of a number of research reports. ValuEngine lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 29th. HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, June 7th. BidaskClub lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 17th. Evercore ISI initiated coverage on Pieris Pharmaceuticals in a report on Monday, March 19th. They set an “outperform” rating and a $13.00 price target on the stock. Finally, Cowen started coverage on Pieris Pharmaceuticals in a report on Friday, May 4th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $12.33.

NASDAQ:PIRS traded down $0.33 during mid-day trading on Thursday, reaching $5.32. The stock had a trading volume of 1,000,600 shares, compared to its average volume of 732,855. The company has a market cap of $314.67 million, a P/E ratio of -13.30 and a beta of 1.65. Pieris Pharmaceuticals has a twelve month low of $4.11 and a twelve month high of $9.75.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.14). The firm had revenue of $4.15 million during the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative net margin of 65.40% and a negative return on equity of 96.56%. analysts predict that Pieris Pharmaceuticals will post -0.48 earnings per share for the current fiscal year.

In other news, insider Orbimed Advisors Llc sold 1,000,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $6.35, for a total transaction of $6,350,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James A. Geraghty purchased 10,000 shares of Pieris Pharmaceuticals stock in a transaction dated Tuesday, May 15th. The shares were bought at an average price of $5.75 per share, with a total value of $57,500.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at approximately $115,000. The disclosure for this purchase can be found here. 4.05% of the stock is owned by company insiders.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Insider Buying and Selling by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply